ClinicalTrials.gg
CompletedNCT01540071Updated May 14, 2021Results posted

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

A Phase 2 interventional study of NRX 194204 in Castration Resistant Prostate Cancer, sponsored by Io Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Io Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
1,716th of 3,023
38 · median 48
Started
2011
with 129 others
Phase 2
1,063 of 3,596
145 open now
Registered
1,267th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,716th largest by enrollment of the 3,023 interventional ones that give a count, is one of 130 that started in 2011, is one of 1,063 in phase 2, and was the 1,267th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

Read the detailed description

Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs (retinoid X receptors). Because NRX 194204 is significantly more selective for the RXRs relative to the RARs (retinoic acid receptors) than a first generation approved drug, it is associated with fewer adverse events in clinical use. This study seeks to investigate NRX 194204 monotherapy in patients with castration- and taxane- resistant prostate cancer.

03

Conditions studied

  • Castration Resistant Prostate Cancer

Browse trials for

Keywords

  • HRPC (Hormone refractory prostate cancer)
  • Androgen independent prostate cancer
  • CRPC (Castration and Taxane Resistant Prostate Cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed prostate cancer
  • Documented progression on at least one prior hormone treatment, AND at least one taxane based chemotherapy regimen, or patient's refusal of chemotherapy treatment
  • Male, Age > 18 years
  • (Eastern Cooperative Oncology Group) performance score of 0-2
  • Adequate bone marrow, renal and hepatic function
  • Men of must consent to use barrier while on treatment and for 90 days thereafter

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with NRX 194204 or bexarotene (Targretin)
  • Presence of parenchymal
  • History of prior within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder or other stage I or stage II cancer in complete remission for at least 12 months
  • Patients with a history of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure or myocardial infarction within 6 months of enrollment
  • Known or or C infection
  • \< 3 months
  • Patients with any history of thyroid disease, pituitary disease or treatment with thyroid replacement hormone
  • Patients with a history of pancreatitis or at significant risk of developing pancreatitis
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    NRX 194204

    This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.

    Drug: NRX 194204

Interventions

  • NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day

    Also known as: Rexinoid

06

What researchers measure

Primary outcomes

  1. Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer

    Clinical benefit will be defined as either non-progression at 8 weeks or radiologic and/or PSA response at any time point with no dose limiting toxicity (DLT) or other toxicity requiring termination of treatment.

    Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years

Secondary outcomes

  1. Overall Survival

    Overall Survival \[Time Frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years\]

    Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years

  2. Time to Disease Progression

    Time to Disease Progression was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. Progression was defined as at least a 20% relative increase and an absolute increase of at least 5mm; or appearance of new lesions.

    Time frame: participants were to be followed for the duration of treatment and follow up; for up to 2.5 years from baseline

  3. Number of Grade 3 and Higher Adverse Events Deemed at Least Possibly Related to NRX 194204

    Number of Grade 3 and higher Adverse Events deemed at least possibly related to NRX 194204

    Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years

  4. PSA Response Rate

    Prostate specific Antigen (PSA) response rate based on 50% reduction from baseline PSA

    Time frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years

07

Results

Posted May 14, 2021

Participant flow

A total of 38 patients were recruited

Participant flow — Overall Study
MilestoneNRX 194204
Started38
Completed38
Not completed0

Outcome measures

PrimaryClinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer

Clinical benefit will be defined as either non-progression at 8 weeks or radiologic and/or PSA response at any time point with no dose limiting toxicity (DLT) or other toxicity requiring termination of treatment.

Time frame:
participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
Reported as:
Count of participants · Participants
Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer
ParticipantsNRX 194204
Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer19
SecondaryOverall Survival

Overall Survival \[Time Frame: participants will be followed for the duration of treatment and follow up, which is up to 2.5 years\]

Time frame:
participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
Reported as:
Mean · days
Overall Survival
daysNRX 194204
Overall Survival312 (38 to 933)
SecondaryTime to Disease Progression

Time to Disease Progression was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. Progression was defined as at least a 20% relative increase and an absolute increase of at least 5mm; or appearance of new lesions.

Time frame:
participants were to be followed for the duration of treatment and follow up; for up to 2.5 years from baseline
Reported as:
Mean · days
Time to Disease Progression
daysNRX 194204
Time to Disease Progression105 (21 to 540)
SecondaryNumber of Grade 3 and Higher Adverse Events Deemed at Least Possibly Related to NRX 194204

Number of Grade 3 and higher Adverse Events deemed at least possibly related to NRX 194204

Time frame:
participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
Reported as:
Number · events
Number of Grade 3 and Higher Adverse Events Deemed at Least Possibly Related to NRX 194204
eventsNRX 194204
Number of Grade 3 and Higher Adverse Events Deemed at Least Possibly Related to NRX 19420423
SecondaryPSA Response Rate

Prostate specific Antigen (PSA) response rate based on 50% reduction from baseline PSA

Time frame:
participants will be followed for the duration of treatment and follow up, which is up to 2.5 years
Reported as:
Number · participants
PSA Response Rate
participantsNRX 194204
partial response1
stable disease6
progressive disease29

Adverse events

Collected over Adverse events were collected as long as each individual patient was receiving study drug, and were further followed for each individual patient for up to a maximum of 2.5 years, or until they were lost to follow-up, or died.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NRX 1942040/38 (0%)13/38 (34.2%)38/38 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventNRX 194204
ConfusionNervous system disorders2/38
Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders2/38
AnemiaBlood and lymphatic system disorders2/38
DyspneaRespiratory, thoracic and mediastinal disorders2/38
DehydrationMetabolism and nutrition disorders2/38
Congestive Heart FailureCardiac disorders2/38
Elevated PTBlood and lymphatic system disorders1/38
Elevated INRBlood and lymphatic system disorders1/38
Elevated PTTBlood and lymphatic system disorders1/38
Deep Vein ThrombosisBlood and lymphatic system disorders1/38
Most frequent other events
Showing 10 of 13
Most frequent other events
EventNRX 194204
HypertriglyceridemiaMetabolism and nutrition disorders15/38
FatigueMetabolism and nutrition disorders13/38
HypothyroidismEndocrine disorders12/38
AnemiaBlood and lymphatic system disorders6/38
LeucocytopeniaBlood and lymphatic system disorders6/38
AnorexiaMetabolism and nutrition disorders5/38
HypercholesterolemiaMetabolism and nutrition disorders5/38
Back PainMusculoskeletal and connective tissue disorders4/38
VomitingGastrointestinal disorders3/38
NauseaGastrointestinal disorders3/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)NRX 194204
Mean71.6 (48 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)NRX 194204
Female0
Male38
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NRX 194204
Hispanic or Latino4
Not Hispanic or Latino31
Unknown or Not Reported3
08

Study locations

1 site
  • Lalita Pandit, MD
    Fountain Valley, California 92708, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2011
First posted
Feb 28, 2012
Start
Aug 2011
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
May 14, 2021
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01540071
Lead sponsor
Io Therapeutics
Responsible party
Sponsor
First posted
Feb 28, 2012
Start date
Aug 2011
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
May 14, 2021
Last update
May 14, 2021

Study contacts

Lalita Pandit, MD
principal investigator · Lalita Pandit, MD

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGN 194204

Start the discussion